DNA binding sites for putative methylation boundaries in the unmethylated region of the BRCA1 promoter

Changes in DNA methylation patterns are frequently observed in human cancers and are associated with a decrease in tumor suppressor gene expression. Hypermethylation of the BRCA1 promoter has been reported in a portion of sporadic breast tumours that correspond to a reduction in BRCA1 transcription and expression. Questions remain concerning the maintenance of methylation free zones in promoter regions of tumor suppressor genes in normal tissues. Sodium bisulfite based analysis of the BRCA1 promoter defines a methylation free zone in normal breast tissue that starts 650 bp upstream of the transcription start site and extends for 1.4 kb through most of the BRCA1 CpG island. We provide data implicating 2 proteins, Sp1 and CTCF, in the maintenance of this methylation‐free zone. Both of these proteins have been shown to function as methylation boundaries in other genes. Four Sp1 sites have been identified in the BRCA1 promoter by gel shift assays. In vivo binding of Sp1 has been confirmed at 2 of these sites in the BRCA1 promoter and at 2 CTCF sites that flank the unmethylated region. Our data suggest that these DNA binding sites for Sp1 and CTCF may act as boundary elements that are important in maintaining genomic integrity by delineating the normal methylation free BRCA1 promoter. Inactivation or disruption of these boundaries may facilitate an epigenetic “hit”, in this case DNA methylation, leading to BRCA1 downregulation and contributing to tumorigenesis, particularly the genesis of sporadic breast tumours. © 2004 Wiley‐Liss, Inc.

[1]  Li Yu,et al.  [DNA methylation and cancer]. , 2005, Zhonghua nei ke za zhi.

[2]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[3]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[4]  M. Nicolás,et al.  Transcriptional regulation of the human Sp1 gene promoter by the specificity protein (Sp) family members nuclear factor Y (NF-Y) and E2F. , 2003, The Biochemical journal.

[5]  R. Ward,et al.  The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. , 2003, The American journal of pathology.

[6]  H. Nagai,et al.  Methylation profile of the MLH1 promoter region and their relationship to colorectal carcinogenesis , 2003, Genes, chromosomes & cancer.

[7]  A. Feinberg,et al.  Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. , 2002, Cancer research.

[8]  B. Tycko,et al.  Chromosome arm 16q in Wilms tumors: Unbalanced chromosomal translocations, loss of heterozygosity, and assessment of the CTCF gene , 2002, Genes, chromosomes & cancer.

[9]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[10]  M. Robert,et al.  An Essential Role for DNA Methyltransferase DNMT3B in Cancer Cell Survival* , 2002, The Journal of Biological Chemistry.

[11]  Bert Vogelstein,et al.  DNMT1 and DNMT3b cooperate to silence genes in human cancer cells , 2002, Nature.

[12]  A. Feinberg,et al.  Tumor-associated zinc finger mutations in the CTCF transcription factor selectively alter tts DNA-binding specificity. , 2002, Cancer research.

[13]  R Ohlsson,et al.  CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. , 2001, Trends in genetics : TIG.

[14]  D. Butcher,et al.  Functional analysis of CpG methylation in the BRCA1 promoter region , 2001, Oncogene.

[15]  Y. Sugiura,et al.  Finger-positional change in three zinc finger protein Sp1: influence of terminal finger in DNA recognition. , 2001, Biochemistry.

[16]  C. Plass,et al.  Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  I. Andrulis,et al.  Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. , 2000, Carcinogenesis.

[18]  C. Deng,et al.  Roles of BRCA1 and its interacting proteins , 2000, BioEssays : news and reviews in molecular, cellular and developmental biology.

[19]  Shirley M. Tilghman,et al.  CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus , 2000, Nature.

[20]  G. Felsenfeld,et al.  Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene , 2000, Nature.

[21]  E. Atlas,et al.  GA-binding protein α/β is a critical regulator of the BRCA1 promoter , 2000, Oncogene.

[22]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[23]  T A Gray,et al.  Conserved characteristics of heterochromatin-forming DNA at the 15q11-q13 imprinting center. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J. Peterse,et al.  Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type , 1999, British Journal of Cancer.

[25]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[26]  J. Herman,et al.  In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Chow,et al.  Somatic mutations in the BRCA1 gene in Chinese sporadic breast and ovarian cancer , 1999, Oncogene.

[28]  Howard Cedar,et al.  DNA methylation represses transcription in vivo , 1999, Nature Genetics.

[29]  Chun-Fang Xu,et al.  Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics , 1999, Oncogene.

[30]  Y. Bignon,et al.  Quantification of BRCA1 protein in sporadic breast carcinoma with or without loss of heterozygosity of the BRCA1 gene , 1999, International journal of cancer.

[31]  Yanfen Hu,et al.  Chromatin remodeling and activation of chromosomal DNA replication by an acidic transcriptional activation domain from BRCA1. , 1999, Genes & development.

[32]  Shiaw-Yih Lin,et al.  Growth/Cell Cycle Regulation of Sp1 Phosphorylation* , 1999, The Journal of Biological Chemistry.

[33]  C. Walsh,et al.  Cytosine methylation and mammalian development. , 1999, Genes & development.

[34]  K. Robertson,et al.  The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. , 1999, Nucleic acids research.

[35]  P. Neiman,et al.  A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers , 1998, Genes, chromosomes & cancer.

[36]  F. O'Malley,et al.  CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site , 1998, Oncogene.

[37]  J. Paterson.  BRCA1: a review of structure and putative functions. , 1998, Disease markers.

[38]  A. Dobrovic,et al.  Methylation of the BRCA1 gene in sporadic breast cancer. , 1997, Cancer research.

[39]  S. Clark,et al.  Sp1 binding is inhibited by mCpmCpG methylation , 1997 .

[40]  P. Ainsworth,et al.  Constitutively methylated CpG dinucleotides as mutation hot spots in the retinoblastoma gene (RB1). , 1997, American journal of human genetics.

[41]  M. Mass,et al.  CpG methylation inactivates the transcriptional activity of the promoter of the human p53 tumor suppressor gene. , 1997, Biochemical and biophysical research communications.

[42]  S. Richard,et al.  Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. , 1997, American journal of human genetics.

[43]  R. Versteeg.  Aberrant methylation in cancer. , 1997, American journal of human genetics.

[44]  J. Jung,et al.  Homonucleotide tracts, short repeats and CpG/CpNpG motifs are frequent sites for heterogeneous mutations in the neurofibromatosis type 1 (NF1) tumour-suppressor gene. , 1997, Mutation research.

[45]  P. Avner,et al.  X-chromosome inactivation in mammals. , 1997, Annual review of genetics.

[46]  P. Ainsworth,et al.  Heterogenous point mutations in the BRCA1 breast cancer susceptibility gene occur in high frequency at the site of homonucleotide tracts, short repeats and methylatable CpG/CpNpG motifs. , 1996, Oncogene.

[47]  P. Jones,et al.  DNA methylation errors and cancer. , 1996, Cancer research.

[48]  R. F. Smith,et al.  BCM Search Launcher--an integrated interface to molecular biology data base search and analysis services available on the World Wide Web. , 1996, Genome research.

[49]  D. Rodenhiser,et al.  Site and sequence specific DNA methylation in the neurofibromatosis (NF1) gene includes C5839T: the site of the recurrent substitution mutation in exon 31. , 1996, Human molecular genetics.

[50]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[51]  M. King,et al.  Inherited breast and ovarian cancer. , 1995, Human molecular genetics.

[52]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[53]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[54]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[56]  S. Clark,et al.  High sensitivity mapping of methylated cytosines. , 1994, Nucleic acids research.

[57]  P. Neiman,et al.  CTCF, a conserved nuclear factor required for optimal transcriptional activity of the chicken c-myc gene, is an 11-Zn-finger protein differentially expressed in multiple forms , 1993, Molecular and cellular biology.

[58]  Rudolf Jaenisch,et al.  Targeted mutation of the DNA methyltransferase gene results in embryonic lethality , 1992, Cell.

[59]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[60]  E. Scarano,et al.  DNA Methylation , 1973, Nature.